menu
    • menu
    [{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Qualigen","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Merger","leadProduct":"Galacto-oligosaccharide","moa":"Lactase enzyme","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ritter Pharmaceuticals \/ Qualigen","highestDevelopmentStatusID":"9","companyTruncated":"Ritter Pharmaceuticals \/ Qualigen"},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Qualigen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Merger","leadProduct":"AS1411","moa":"Nucleolin","graph1":"Oncology","graph2":"Phase III","graph3":"Ritter Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ritter Pharmaceuticals \/ Qualigen","highestDevelopmentStatusID":"10","companyTruncated":"Ritter Pharmaceuticals \/ Qualigen"}]

    Find Clinical Drug Pipeline Developments & Deals by Ritter Pharmaceuticals

    Menu

    Ritter Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ritter Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ritter Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AS1411

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Qualigen

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen ...

                            Details : Qualigen offers a number of revenue-generating therapeutic and diagnostic products that may help Ritter Pharmaceuticals to advance its pipeline and grow its business.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 28, 2020

                            Lead Product(s) : AS1411

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Qualigen

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ritter Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ritter Pharmaceuticals

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galacto-oligosaccharide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Qualigen

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement

                            Details : The merged company will focus on the development of Qualigen’s nanotechnology therapies for the treatment of cancer and infectious diseases, while also continuing to operate its profitable diagnostic business.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 21, 2020

                            Lead Product(s) : Galacto-oligosaccharide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Qualigen

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth